Dordaviprone
Brand names: Modeyso · Active ingredient: Dordaviprone
In short: MODEYSO is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. This indication is approved under accelerated approval based on overall response rate and duratio
What is Dordaviprone used for?
MODEYSO is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.
This indication is approved under accelerated approval based on overall response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Dordaviprone dosage
Select patients for treatment with MODEYSO based on the presence of an H3 K27M mutation from tumor specimens . An FDA-approved test for the detection of this mutation is not currently available.
Monitor electrocardiograms (ECG) and electrolytes before starting MODEYSO and periodically during treatment as clinically indicated .
Take MODEYSO on an empty stomach, at least 1 hour before or 3 hours after food intake .
Adults
The recommended dosage of MODEYSO is 625 mg orally once weekly.
Pediatrics
The recommended dosage of MODEYSO in pediatric patients aged 1 to <17 years who weigh at least 10 kg is based on body weight (Table 1). A recommended dosage of MODEYSO has not been established in pediatric patients who weigh less than 10 kg.
Body Weight (kg) | Recommended Dosage
10 kg to <12.5 kg | 125 mg Once Weekly
12.5 kg to <27.5 kg | 250 mg Once Weekly
27.5 kg to <42.5 kg | 375 mg Once Weekly
42.5 kg to <52.5 kg | 500 mg Once Weekly
≥52.5 kg | 625 mg Once Weekly
Continue MODEYSO until disease progression or unacceptable toxicity.
Swallow capsules whole. For patients unable to swallow capsules whole, open each capsule, mix contents with approximately 15 to 30 mL of liquid (sports drink, apple juice, lemonade, or water) before administration, and administer orally as a liquid . Once mixed, administer within 2 hours of preparation, or discard and mix a new dose.
Vomiting
If vomiting occurs after taking a dose, do not take an additional dose and take the next dose at the regularly scheduled time.
Missed Dose
If a dose is missed within 2 days, take the missed dose as soon as possible. If a dose is missed by more than 2 days, skip the missed dose and take the next dose at the scheduled time.
The recommended dosage reductions for adverse reactions for MODEYSO are provided in Table 2.
Patient’s Weight (kg) | First Dosage Reduction | Second Dosage Reduction
Pediatric patients 10 kg to <12.5 kg | Permanently discontinue | N/A
Pediatric patients 12.5 kg to <27.5 kg | 125 mg once weekly | Permanently discontinue
Pediatric patients 27.5 kg to <42.5 kg | 250 mg once weekly | 125 mg once weekly
Pediatric patients 42.5 kg to <52.5 kg | 375 mg once weekly | 250 mg once weekly
Pediatric patients ≥52.5 kg and adult patients | 500 mg once weekly | 375 mg once weekly
The recommended dosage modifications for adverse reactions are provided in Table 3.
Adverse Reaction | Severitya | Dosage Modificationb
Hypersensitivity
| Any grade | If hypersensitivity is suspected based on clinical judgement, interrupt MODEYSO until resolution of the event.
Permanently discontinue MODEYSO in patients who develop serious hypersensitivity reactions. …
How to take Dordaviprone — instructions & advice from the label
Advise the patient and caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Hypersensitivity
Advise patients that MODEYSO can cause hypersensitivity. Inform patients about the signs and symptoms of hypersensitivity reactions and instruct patients or caregivers to seek immediate medical attention if symptoms occur .
QTc Interval Prolongation
Advise patients that MODEYSO can cause QTc interval prolongation. Inform patients of the signs and symptoms of QTc prolongation and instruct patients or caregivers to seek immediate medical attention if symptoms occur .
Drug Interactions
Inform patients that MODEYSO may interact with some drugs. Advise patients to inform their healthcare provider about all medications they are taking, including prescription and over-the-counter drugs, vitamins, and herbal products. Additionally, patients should consult their healthcare provider before starting or stopping any prescription drug, nonprescription drug, or supplement . …
Warnings & precautions
Do not take this medicine if: None.
MODEYSO can cause severe hypersensitivity reactions.
In the pooled safety population , Grade 3 hypersensitivity reactions occurred in 0.3% of patients receiving MODEYSO. Signs and symptoms of hypersensitivity may include rash, hives, fever, low blood pressure, wheezing, or swelling of the face or throat.
Inform patients about the signs and symptoms of hypersensitivity reactions and instruct them to seek immediate medical attention if symptoms occur.
If clinically significant hypersensitivity or anaphylaxis occur, immediately interrupt MODEYSO and initiate appropriate medical treatment and supportive care. Based on the severity of the adverse reaction, temporarily interrupt or permanently discontinue MODEYSO .
MODEYSO causes a concentration-dependent QTc interval prolongation , which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death.
In the pooled safety population , of the 82 patients who underwent at least one post-baseline ECG assessment, 6% experienced an increase in QTc of >60 msec compared to baseline after receiving MODEYSO and 1.2% had an increase in QTc to >500 msec.
Monitor ECGs and electrolytes prior to starting MODEYSO and then periodically during treatment as clinically indicated.
Significant prolongation of the QT interval may occur when MODEYSO is taken concomitantly with other products that have a known potential to prolong the QT interval. Avoid concomitant use of MODEYSO with products known to prolong the QT interval. If concomitant use cannot be avoided, separate administration of MODEYSO and the QT-prolonging product . …
Dordaviprone side effects
The following potential clinically significant adverse reactions are described elsewhere in the labelling:
•Hypersensitivity .
•QTc Interval Prolongation .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in WARNINGS AND PRECAUTIONS and below reflects exposure to MODEYSO at the recommended weight-based dose taken until disease progression or unacceptable toxicity in 376 adult and pediatric patients with glioma across four open-label clinical studies (ONC006, ONC013, ONC014, and ONC018) .
Of the 376 patients who received MODEYSO, 35% were exposed for 6 months, and 17% were exposed for 1 year.
The median age was 23 years (range: 3 to 80): 30% were 2 to 11 years old, 11% were 12 to 17 years old, 55% were 18 to 64 years old, and 3.7% were 65 years or older. Fifty-two percent (52%) were female; 74% White, 10% unknown race or race not reported, 9% Black or African American, 4% Asian, 2.9% other or multiple races; and 13% were of Hispanic or Latino ethnicity. Karnofsky/Lansky Performance Status (KPS/LPS) score was 80 to 100 in 66% of patients, 60 to 70 in 27%, and <60 in 7%. …
Drug interactions
Table 6 describes drug interactions where concomitant use of another drug affects MODEYSO.
Strong and Moderate CYP3A4 Inhibitors
Prevention or Management | •Avoid concomitant use of strong and moderate CYP3A4 inhibitors with MODEYSO.
•If concomitant use cannot be avoided for adults and pediatric patients who weigh at least 52.5 kg, reduce the MODEYSO dose as recommended .
Mechanism and Clinical Effects | •Dordaviprone is a CYP3A4 substrate.
•Strong and moderate CYP3A4 inhibitors increase dordaviprone exposure , which may increase the risk of MODEYSO‑related adverse reactions .
Strong or Moderate CYP3A4 Inducers
Prevention or Management | •Avoid concomitant use of strong and moderate CYP3A4 inducers with MODEYSO.
Mechanism and Clinical Effects | •Dordaviprone is a CYP3A4 substrate.
•Strong and moderate CYP3A4 inducers decrease dordaviprone exposure , which may reduce the anti-tumor activity of MODEYSO.
Table 7 describes drug interactions associated with QTc interval prolongation when used concomitantly with MODEYSO.
Products that Prolong QTc Interval
Prevention or Management | •Avoid concomitant use of MODEYSO with products known to prolong the QTc interval.
•If concomitant use cannot be avoided, separate administration of MODEYSO and the QT-prolonging product . …
About this medicine
Dordaviprone is a protease activator.
Dordaviprone is present as dordaviprone hydrochloride with the molecular formula C24H26N4O•2HCl. The molecular weight is 459.41. The full chemical name for dordaviprone hydrochloride is 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one dihydrochloride.
Dordaviprone hydrochloride has the following chemical structure:
Dordaviprone hydrochloride is a white to off-white solid that is freely soluble in water. The 1% solution of dordaviprone hydrochloride is measured as pH 3.3.
MODEYSO (dordaviprone) capsules are supplied as 125 mg strength capsules in an immediate‑release oral formulation. Each MODEYSO capsule contains 125 mg of dordaviprone (equivalent to 148.8 mg of dordaviprone hydrochloride).
The inactive ingredients in the capsule include magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The capsule shell consists of hypromellose and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ad45b43e-fdef-47ad-9c34-055b41bdc576. Read the full official label on DailyMed.